Home Apoptosis -Immunology & Inflammation -Cell Cycle PD-1/PD-L1

PD-1/PD-L1

Apoptosis

BET Histone Demethylase Histone Methyltransferase Epigenetic Reader Domain Histone Acetyltransferase Histone MicroRNA NSD EZH2 RNA Methyltransferase SF3B TET

Isoform-selective Products

  • All (12)
  • PD-1/PD-L1 Inhibitors (12)
  • New PD-1/PD-L1 Products
Cat.No. Product Name Information Product Use Citations Product Validations
S7912 BMS202 BMS202 is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM.
Front Immunol, 2025, 16:1529710
Front Oncol, 2025, 15:1572040
Sci Rep, 2025, 15(1):26918
S7911 BMS-1 BMS-1 is a small-molecule inhibitor of PD-1/PD-L1 interaction with IC50 of 6 nM.
Theranostics, 2025, 15(9):3924-3942
J Med Chem, 2024, 67(5):4036-4062
PLoS Comput Biol, 2024, 20(11):e1012284
S8158 PD-1/PD-L1 Inhibitor 3 PD-1/PD-L1 Inhibitor 3（Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 3）is a Macrocyclic inhibitor of PD-1/PD-L1 interaction with IC50 of 5.6 nM
ACS Appl Mater Interfaces, 2024, 16(18):22839-49
J Med Chem, 2024, 67(5):4036-4062
Front Oncol, 2024, 14:1536406
S8275 Tomivosertib (eFT-508) Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. This compound inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.
Nat Commun, 2024, 15(1):9755
Nat Commun, 2024, 15(1):9755
J Clin Invest, 2024, 134(16)e168393
S8859 BMS-1166 BMS-1166 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 interaction with an IC50 of 1.4 nM.
Int J Mol Sci, 2025, 26(14)6876
iScience, 2024, 27(7):110243
Life Sci Alliance, 2024, 10.26508/lsa.202302461
S8549 AUNP-12 AUNP-12 (Aur-012, Aurigene-012, Aurigene NP-12), a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.
Acta Pharm Sin B, 2024, 14(1):350-364
Carcinogenesis, 2022, bgac043
Molecules, 2019, 24(15)
S0094 SR 0987 SR 0987, a SR 1078 analog, is an agonist for T cell-specific RORγ (RORγt) with EC50 of 800 nM. This compound represses PD-1, produces IL17 and is potential for the treatment of cancer.
Evid Based Complement Alternat Med, 2022, 2022:8315503.
E1322 GS-4224 GS-4224 (Evixapodlin, PD-1/PD-L1-IN 7) is an inhibitor of human PD-1/PD-L1 protein/protein interaction with an IC50 of 0.213 nM. It enhances IFN-γ and Granzyme B Production in chronic hepatitis B (CHB) CD8+ T Cells and CD4+ T Cells. It exhibits anticancer and antiviral functions.
S8473 CA-170 (AUPM-170) CA-170 (AUPM-170, PD-1-IN-1) is a potent and orally available inhibitor of the immune checkpoint regulatory proteins PD-L1 (programmed cell death ligand-1) and VISTA (V-domain immunoglobulin (Ig) suppressor of T-cell activation). This compound exhibits anti-tumor efficacy.
S9610 BMS-1001 BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. This compound alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes.
E3151 Sanguisorbae Radix Extract Sanguisorbae Radix Extract is extracted from Sanguisorbae Radix, which has anticancer effects by inhibiting PD-1/PD-L1 and also enhances immuno-oncologic effects.
S9863 INCB086550 INCB086550 (PD-1/PD-L1-IN-8) is a potent PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM. This compound binds to PD-L1 and interrupts its interaction with PD-1 and also induces PD-L1 dimerization and internalization.
In Vivo, 2025, 39(1):80-95
S7912 BMS202 BMS202 is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM.
Front Immunol, 2025, 16:1529710
Front Oncol, 2025, 15:1572040
Sci Rep, 2025, 15(1):26918
S7911 BMS-1 BMS-1 is a small-molecule inhibitor of PD-1/PD-L1 interaction with IC50 of 6 nM.
Theranostics, 2025, 15(9):3924-3942
J Med Chem, 2024, 67(5):4036-4062
PLoS Comput Biol, 2024, 20(11):e1012284
S8158 PD-1/PD-L1 Inhibitor 3 PD-1/PD-L1 Inhibitor 3（Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 3）is a Macrocyclic inhibitor of PD-1/PD-L1 interaction with IC50 of 5.6 nM
ACS Appl Mater Interfaces, 2024, 16(18):22839-49
J Med Chem, 2024, 67(5):4036-4062
Front Oncol, 2024, 14:1536406
S8275 Tomivosertib (eFT-508) Tomivosertib (eFT-508) is a potent and selective MNK1/2 inhibitor with IC50s of 2.4 nM and 1 nM, respectively. It potentially results in decreased tumor cell proliferation and tumor growth. This compound inhibits eIF4E phosphorylation and dramatically downregulates PD-L1 protein abundance.
Nat Commun, 2024, 15(1):9755
Nat Commun, 2024, 15(1):9755
J Clin Invest, 2024, 134(16)e168393
S8859 BMS-1166 BMS-1166 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 interaction with an IC50 of 1.4 nM.
Int J Mol Sci, 2025, 26(14)6876
iScience, 2024, 27(7):110243
Life Sci Alliance, 2024, 10.26508/lsa.202302461
S8549 AUNP-12 AUNP-12 (Aur-012, Aurigene-012, Aurigene NP-12), a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.
Acta Pharm Sin B, 2024, 14(1):350-364
Carcinogenesis, 2022, bgac043
Molecules, 2019, 24(15)
S0094 SR 0987 SR 0987, a SR 1078 analog, is an agonist for T cell-specific RORγ (RORγt) with EC50 of 800 nM. This compound represses PD-1, produces IL17 and is potential for the treatment of cancer.
Evid Based Complement Alternat Med, 2022, 2022:8315503.
E1322 GS-4224 GS-4224 (Evixapodlin, PD-1/PD-L1-IN 7) is an inhibitor of human PD-1/PD-L1 protein/protein interaction with an IC50 of 0.213 nM. It enhances IFN-γ and Granzyme B Production in chronic hepatitis B (CHB) CD8+ T Cells and CD4+ T Cells. It exhibits anticancer and antiviral functions.
S8473 CA-170 (AUPM-170) CA-170 (AUPM-170, PD-1-IN-1) is a potent and orally available inhibitor of the immune checkpoint regulatory proteins PD-L1 (programmed cell death ligand-1) and VISTA (V-domain immunoglobulin (Ig) suppressor of T-cell activation). This compound exhibits anti-tumor efficacy.
S9610 BMS-1001 BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. This compound alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes.
E3151 Sanguisorbae Radix Extract Sanguisorbae Radix Extract is extracted from Sanguisorbae Radix, which has anticancer effects by inhibiting PD-1/PD-L1 and also enhances immuno-oncologic effects.
S9863 INCB086550 INCB086550 (PD-1/PD-L1-IN-8) is a potent PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM. This compound binds to PD-L1 and interrupts its interaction with PD-1 and also induces PD-L1 dimerization and internalization.
In Vivo, 2025, 39(1):80-95